

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
17 June 2004 (17.06.2004)

PCT

(10) International Publication Number  
**WO 2004/050913 A1**

- (51) International Patent Classification<sup>7</sup>: C12Q 1/68, A61K 31/00, A61P 25/28
- (21) International Application Number: PCT/GB2003/005131
- (22) International Filing Date: 26 November 2003 (26.11.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0228079.0 2 December 2002 (02.12.2002) GB
- (71) Applicant (for all designated States except US): LAX-DALE LIMITED [GB/GB]; Kings Park House, Laurelhill Business Park, Polmaise Road, Stirling FK7 8JQ (GB).
- (71) Applicant and
- (72) Inventor (for US only): HORROBIN, David, Frederick [GB/GB]; Laxdale Limited, Kings Park House, Laurelhill Business Park, Polmaise Road, Stirling FK7 9JQ (GB).
- (74) Agent: WAKERLEY, Helen, Rachael; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/050913 A1

(54) Title: TREATMENT OF HUNTINGTON'S DISEASE WITH EPA

(57) Abstract: Analysis of the huntington gene provides a method for identifying patients likely to respond to treatment of Huntington's disease with eicosapentaenoic acid, EPA.